The Greek parliament announced on Tuesday the results of a judicial investigation into alleged bribes paid to public officials by Basel-based NovartisExternal link over nearly a decade to boost subscriptions of their products at public hospitals.
“This is a massive scandal that has stunned Greek society,” government spokesman Dimitris Tzanakopoulos said.
Under Greek law, politicians do not face prosecution directly from judicial authorities. Allegations must first be referred to parliament for review before lawmakers vote to strip the accused of their automatic immunity.
The politicians named include current Bank of Greece governor Yannis Stournaras and EU Home Affairs Commissioner Dimitris Avramopoulos, plus former conservative prime minister Antonis Samaras, the caretaker prime minister Panagiotos Pikramenos in 2012 and five former health ministers. They have all denied the allegations.
Samaras, the former conservative prime minister who served between 2012 and 2015, said the allegations against him were politically motivated, and vowed to file a lawsuit against left-wing Prime Minister Alexis Tsipras.
“This is the most ruthless but also most ridiculous conspiracy ever,” he said.
Novartis said it is cooperating with Greek authorities.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
New Novartis chief eyes productivity revolution
This content was published on
Vas Narasimhan estimates that using digital technology more efficiently could save up to 25% on the cost of clinical trials.
Will exclusive collaborations yield more drug breakthroughs?
This content was published on
Recently FDA-approved, Novartis's pioneering immunotherapy was developed through an agreement with University of Pennsylvania researchers.
Pharma turns to big data to gauge care and pricing
This content was published on
Struggling to keep pace with digitisation, big pharma companies are turning to big data to drive future growth. Swiss-based Novartis is no different.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.